Your Antidepressant May Not Affect Ketamine Outcomes

New Research Eases a Common Concern About Combining Ketamine With Antidepressants

A study published in April 2026 in The Journal of Clinical Psychiatry is offering meaningful reassurance to the many patients who enter ketamine treatment while still taking an oral antidepressant. The research found no statistically significant differences in clinical outcomes between patients using SSRIs, SNRIs, or other classes of antidepressants concurrently with either intravenous (IV) ketamine or intranasal esketamine (Spravato).

In plain terms: the type of antidepressant you're currently taking doesn't appear to meaningfully help or hurt how well ketamine works for you. That's a notable finding — and one that carries real practical weight for patients navigating the decision to start ketamine therapy while remaining on existing psychiatric medications.

The study examined outcomes across a real-world patient population, comparing groups defined by their concurrent antidepressant class. Across those groups — SSRI users, SNRI users, and those on other antidepressant types — no group showed significantly better or worse clinical results. The findings applied to both IV ketamine administered in clinical settings and to intranasal esketamine, which is FDA-approved and frequently used in certified outpatient treatment centers.

This kind of comparative effectiveness data is still relatively new in the ketamine field. Researchers and clinicians have long operated with incomplete information about how existing pharmacological regimens interact with ketamine's mechanisms. This study helps fill that gap — and the takeaway is more permissive than many patients and providers might have expected.

Why This Question Matters — and Why It's Been Hard to Answer

Ketamine works through a fundamentally different pathway than conventional antidepressants. While SSRIs and SNRIs modulate serotonin and norepinephrine systems over weeks of use, ketamine acts primarily on NMDA glutamate receptors and produces rapid antidepressant effects — often within hours to days. Because these mechanisms are so different, there has been genuine scientific debate about whether the presence of a serotonergic or noradrenergic agent in a patient's system could amplify, blunt, or otherwise modify ketamine's effects.

Some providers historically recommended tapering or discontinuing certain antidepressants before beginning ketamine therapy — a protocol that introduced its own risks, including destabilization of mood during the transition period. Other providers took a more pragmatic approach and treated patients on stable antidepressant regimens without adjustment. Without strong evidence either way, these decisions were often made by clinical judgment alone.

The new research supports the more pragmatic position. It does not, of course, address every possible drug combination or individual patient variation — and it should not be read as a blanket endorsement of starting ketamine without thoughtful medication review. But it does suggest that a patient arriving at a ketamine clinic on a stable SSRI regimen is not automatically at a disadvantage compared to a patient who has tapered off.

This is particularly relevant for treatment-resistant depression patients, who by definition have often tried multiple antidepressant regimens. Many enter the ketamine conversation still on one or more medications — not because those medications are working well, but because discontinuing them mid-treatment carries its own risks. The reassurance that ketamine can still be effective in that context is clinically significant.

Implications for the Telehealth Ketamine Landscape

For patients exploring online ketamine treatment, this study has direct implications for how intake and screening conversations should unfold. One of the most common concerns we hear from prospective patients is a version of the same question: I'm already on an antidepressant — does that mean ketamine won't work for me, or that I have to stop my medication first?

Based on this research, the honest answer is increasingly: not necessarily. Ketamine's effectiveness does not appear to hinge on which antidepressant class you're taking concurrently. That said, the critical word in this study's findings is class — it looked at broad antidepressant categories, not every specific drug or dosage. Individual medications carry their own interaction profiles, and a thorough medication review by a qualified provider remains an essential part of the intake process.

What this means practically is that patients should not self-screen out of ketamine treatment simply because they are on an SSRI or SNRI. But it also means that any online ketamine provider worth trusting will still conduct a complete medication review at intake — not to identify reasons to exclude you, but to ensure your specific regimen is accounted for and that your treatment plan is appropriately personalized.

When evaluating online ketamine providers, ask directly: How do you handle patients on concurrent antidepressants? Do you require medication changes before starting treatment? What does your prescribing team review at intake? A provider who either dismisses your current medications without review, or who reflexively requires discontinuation of a stable regimen without clinical justification, may not be applying current evidence to your care.

What to Bring to Your Intake Consultation

This research is a reason for cautious optimism, not complacency. Here's how to put it to practical use as you consider online ketamine treatment:

• Be transparent about your full medication list. Include dosages and how long you've been on each medication. The study's findings are reassuring at the category level, but your prescriber needs specifics to make safe, individualized decisions.
• Ask about your provider's protocol for concurrent antidepressants. A reputable telehealth ketamine provider will have a clear position on this, informed by current evidence. The answer should not be a blanket refusal or blanket approval — it should reflect clinical thinking.
• Understand that medication review is a safety step, not a barrier. The goal of intake screening is to make your treatment as effective and safe as possible, not to find reasons to exclude you. New evidence like this study is part of what good providers integrate into those conversations.
• Don't discontinue medications on your own before starting ketamine. Stopping an antidepressant abruptly — especially without guidance from a prescriber — can destabilize mood and introduce risks that outweigh any theoretical benefit of a clean slate going into treatment.

The broader signal from research like this is that the ketamine field is maturing. Studies are moving from early proof-of-concept work toward the kind of comparative effectiveness and real-world evidence that clinicians need to make nuanced treatment decisions. For patients, that means more answers, fewer assumptions, and increasingly personalized care.

Read the original research at Psychiatrist.com.